UCI Child Development Center
Irvine, California, 92612, United States
NCT Number: NCT00580814
The purpose of the study is to investigate the functional state of dopamine cells and the dopamine transporter in ADHD subjects and controls to assess the effects of chronic methylphenidate treatment on dopamine cell function and dopamine transporter levels in ADHD subjects.
Looking for future studies?
Notify Me18 year–45 year
All sexes
Interventional
Not applicable
Irvine, California, 92612, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
subjects received mehtylphenidate treatment for 12 months
Other names: methylphenidate once daily for 12 months, doses individually titrated for efficacy
Time frame: 1 year
Striatal DAT availability as noted in PET scans post one year of methylphenidate treatment or no intervention.
The unit listed as binding potential (BPND) was measured with a dynamic PET scan protocol, using carbon-11 labeled cocaine, a radioligand with specific binding to DAT (which is inhibited by drugs that block DAT but not by drugs that block the norephephrine or serotonin transporters). This radiotracer was utilized to quantify DAT availability as non-displaceable binding potential using a standard kinetic model for reversible ligands.
The dynamic PET scans were started immediately after injection of [11C]cocaine (specific activity 0.5-1.5 Ci/uM at end of bombardment). Arterial blood was obtained to measure the concentration of unchanged [11C] cocaine in plasma for quantification of DAT availability.
University of California, Irvine
Other
Acronym: Brookhaven
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05631626
ADHD, ADHD - Combined Type
Las Vegas, Nevada, United States
View Trial DetailsNCT05588713
Attention Deficit Disorder with Hyperactivity, Attention Deficit Hyperactivity Disorder
Uppsala, Sweden
View Trial DetailsNCT04561713
Attention Deficit Disorder with Hyperactivity, Attention Deficit Hyperactivity Disorder
Bordeaux, France
View Trial DetailsNCT05464056
Attention Deficit Disorder with Hyperactivity, Attention Deficit Hyperactivity Disorder
Chicago, Illinois, United States
View Trial Details